logo

Urogen Pharma Ltd. (URGN)



Trade URGN now with
  Date
  Headline
5/21/2018 2:46:21 PM UroGen Pharma Announces Positive Interim Results From Pivotal Phase 3 OLYMPUS Trial Of UGN-101
5/15/2018 8:06:55 AM UroGen Pharma Posts Q1 Net Loss Of $13.4 Mln Or $0.88 Per Share
4/3/2018 8:37:01 AM UroGen Announces Presentation Of Results From Interim Analysis Of Pivotal Phase 3 OLYMPUS Trial Of UGN-101
3/15/2018 7:07:07 AM UroGen Pharma Q4 Net Loss $10.07 Mln Or $0.74/Shr Vs Income $12.9 Mln Or $1.56/Shr Last Year
2/14/2018 8:05:00 AM UroGen Pharma Appoints Stephen Mullennix As COO
11/27/2017 8:44:54 AM UroGen Pharma Reports Oral Presentation At Society Of Urologic Oncology Annual Meeting
11/14/2017 7:13:44 AM UroGen Pharma Q3 Net Loss Of $0.3 Mln Or $0.02/shr Vs. Loss $8.0 Mln Or $3.73/shr Prior Year
11/6/2017 8:36:12 AM UroGen Says First Patient Enrolled In Allergan Phase 2 Clinical Trial Of RTGel In Combination With BOTOX
10/26/2017 8:52:50 AM UroGen Pharma Appoints Jeffrey Bova As VP Of Commercial And James Ottinger As VP Of Regulatory Affairs
9/6/2017 8:35:18 AM UroGen Pharma Appoints Paul Chu VP Of Business Development